5 reasons for keeping your ESRD patients at home

1: PRESERVING RESIDUAL RENAL FUNCTION

PD patients averaged 30% higher rGFR than HD patients over a 12-month period (P<.0001).¹

2: IMPROVED EARLY SURVIVAL RATES

PD has shown improved survival within the first year compared with HD.²

3: REDUCED COVID-19 HOSPITALIZATIONS

The rate of COVID-19 hospitalizations among patients undergoing hemodialysis was between 3 and 4 times higher than among patients performing peritoneal dialysis.³

4: PATIENT SATISFACTION

PD patients have an 85% higher likelihood of excellent satisfaction vs HD patients.⁴ 80% of ESRD patients are medically eligible for PD⁵ and 50% choose PD over HD when balanced choices are provided.⁶

5: COST-EFFECTIVE THERAPY

Average annual cost of supporting chronic dialysis for a PD patient is $34,300 as compared to an ICHD patients is $39,935.⁷The ESRD Treatment Choices Model now offers additional reimbursement for nephrologists and dialysis clinics for the use of home therapies, including PD.

Call 1-800-284-4060 for your local Baxter representative who can provide resources that help you grow your PD program.

References

Jansen MA, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002;62:1046-1053.
United States Renal Data System. 2016 USRDS Annual Data Report: Vol. 2 – ESRD in the United States. Ch. 6:395-396.
United States Renal Data System (USRDS). 2020 Annual Data Report, COVID-19 Supplement: https://adr.usrds.org/2020/covid-19-supplement/1-covid-19-supplement.
Rubin HR, et al. Patient Ratings of Dialysis Care With Peritoneal Dialysis vs Hemodialysis. JAMA 2004;291:697-703.
Mendelssohn DC, et al. A prospective evaluation of renal replacement therapy modality eligibility. Nephrol Dial Transplant. 2009; 24(2):555-561.
Prieto-Velasco M, Quiros P, Remon C, Spanish Group for the Implementation of a Shared Decision Making Process for RRT Choice with Patient Decision Aid Tools The Concordance between Patients’ Renal Replacement Therapy Choice and Definitive Modality: Is It a Utopia? PLoS ONE 10(10) 2015;e0138811. doi:10.1371/journal. pone.0138811.
NRAA Benchmarking Tool analysis of the 2017 chronic dialysis provider cost reports – Prepared by Prima Health Analytics. Cost of supporting PD includes salaries, benefits, supplies, ESA, all other drug costs excluding ESAs, lab, plant & equipment, administrative & general costs.